Table 5 Deregulated pathways in canine OS pertaining to aggressive phenotype
Reference | Present study on canine osa | Srivastava et al., 2006 | Rajkumar, T. et al., 2008 | Srivastava et al., 2006 |
|---|---|---|---|---|
Study approach | poor survival associated profile | high metastatic profile | drug resistant profile | osteogenic tumor profile |
Samples used | 32 primary tumors | human osa cell lines | cell line resistant to doxorubicin | 10 tumors and 8 normal bones |
Total differential expressed genes | 1426 | 1999 | 485 | 194 |
Total Mapped IDs on PANTHER® | 533 | 1185 | 295 | 159 |
Huntington disease | 12 | â–² | â–² | Â |
Wnt signaling pathway | 10 | â–² | â–² | â–² |
Chemokine/cytokine signaling pathway | 8 | â–² | â–² | â–² |
Integrin signalling pathway | 7 | â–² | Â | â–² |
Parkinson disease | 6 | Â | â–² | â–² |
Ubiquitin proteasome pathway | 6 | Â | â–² | Â |
Alzheimer disease-presenilin pathway | 5 | â–² | â–² | â–² |
Cadherin signaling pathway | 5 | Â | â–² | Â |
Endothelin signaling pathway | 5 | Â | Â | Â |
Glycolysis | 5 | Â | Â | Â |
Heterotrimeric G-protein signaling pathway | 4 | â–² | Â | Â |
Angiogenesis | 3 | Â | Â | â–² |
Cytoskeletal regulation by Rho GTPase | 3 | â–² | Â | Â |
EGF receptor signaling pathway | 3 | â–² | Â | Â |
FGF signaling pathway | 3 | â–² | â–² | â–² |
p53 pathway | 3 | Â | â–² | Â |
PDGF signaling pathway | 3 | â–² | â–² | â–² |
T cell activation | 3 | â–² | â–² | Â |
TGF-beta signaling pathway | 3 | â–² | Â | â–² |
Androgen/estrogene/progesterone biosynthesis | 2 | Â | Â | Â |
Apoptosis signaling pathway | 2 | â–² | â–² | â–² |
B cell activation | 2 | Â | Â | Â |
Hedgehog signaling pathway | 2 | Â | Â | Â |
Hypoxia response via HIF activation | 2 | Â | Â | Â |
Interferon-gamma signaling pathway | 2 | Â | Â | Â |
Interleukin signaling pathway | 2 | â–² | â–² | â–² |
Oxidative stress response | 2 | Â | Â | Â |
p53 pathway feedback loops 2 | 2 | Â | â–² | Â |
PI3 kinase pathway | 2 | â–² | â–² | Â |
Ras Pathway | 2 | â–² | Â | â–² |